Skip to main content
Midas Edge

Revolution Medicines, Inc.

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

RVMD$193.06-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholdersʼ
SharesAmountCapitalIncome/ (Loss)DeficitEquity
Balance at December 31, 2024185,896,625$18$4,001,666$1,321$(1,737,801)$2,265,204
Issuance of common stock pursuant to stock option exercises90,043—891——891
Issuance of common stock related to vesting of restricted stock units271,536—————
Exercise of warrants2—1——1
Stock-based compensation expense——25,084——25,084
Net unrealized gain on marketable securities———386—386
Net loss————(213,416)(213,416)
Balance at March 31, 2025186,258,206184,027,6421,707(1,951,217)2,078,150
Issuance of common stock pursuant to stock option exercises121,103—1,937——1,937
Issuance of common stock related to vesting of restricted stock units361,975—————
Issuance of common stock related to employee stock purchase plan159,984—4,644——4,644
Stock-based compensation expense——28,830——28,830
Net unrealized loss on marketable securities———(405)—(405)
Net loss————(247,787)(247,787)
Balance at June 30, 2025186,901,268184,063,0531,302(2,199,004)1,865,369
Issuance of common stock pursuant to stock option exercises290,805—4,145——4,145
Issuance of common stock related to vesting of restricted stock units344,956—————
Exercise of warrants11—3——3
Issuance of common stock pursuant to exercise of prefunded warrants2,173,911—————
Stock-based compensation expense——30,779——30,779
Net unrealized gain on marketable securities———1,814—1,814
Net loss————(305,206)(305,206)
Balance at September 30, 2025189,710,951$18$4,097,980$3,116$(2,504,210)$1,596,904

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share data)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholdersʼ
SharesAmountCapitalLossDeficitEquity
Balance at December 31, 2023164,674,594$16$2,963,342$544$(1,137,708)$1,826,194
Issuance of common stock pursuant to stock option exercises73,342—810——810
Issuance of common stock related to vesting of restricted stock units165,078—————
Stock-based compensation expense——16,208——16,208
Net unrealized loss on marketable securities———(1,742)—(1,742)
Net loss————(116,003)(116,003)
Balance at March 31, 2024164,913,014162,980,360(1,198)(1,253,711)1,725,467
Issuance of common stock pursuant to stock option exercises238,793—4,340——4,340
Issuance of common stock related to vesting of restricted stock units303,953—————
Issuance of common stock related to employee stock purchase plan190,748—3,164——3,164
Stock-based compensation expense——19,775——19,775
Net unrealized loss on marketable securities———(665)—(665)
Net loss————(133,233)(133,233)
Balance at June 30, 2024165,646,508163,007,639(1,863)(1,386,944)1,618,848
Issuance of common stock pursuant to stock option exercises218,318—3,001——3,001
Issuance of common stock related to vesting of restricted stock units255,934—————
Issuance of common stock upon at-the-market offering1,627,576—74,293——74,293
Stock-based compensation expense——20,775——20,775
Net unrealized gain on marketable securities———5,675—5,675
Net loss————(156,288)(156,288)
Balance at September 30, 2024167,748,336$16$3,105,708$3,812$(1,543,232)$1,566,304
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.